<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148092" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Abaloparatide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akel</surname>
            <given-names>Miis</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Miis Akel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148092.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), is used to manage and treat&#x000a0;osteoporosis. Osteoporosis is characterized by reduced bone mineral density due to changes in bone microstructure, resulting in an elevated risk of fractures. The US Food and Drug Administration (FDA) has approved abaloparatide use&#x000a0;in postmenopausal women at high risk of fracture due to osteoporosis. In addition, abaloparatide is frequently prescribed for individuals who exhibit intolerance to or have not responded to conventional osteoporosis treatments.</p>
        <p>In a double-blind, controlled, randomized phase II clinical trial, the safety and efficacy of abaloparatide&#x000a0;demonstrated superiority in enhancing overall bone mineral density compared to&#x000a0;teriparatide and placebo within these treatment groups. As osteoporosis primarily affects postmenopausal women, it is&#x000a0;crucial to provide clinicians with essential knowledge about abaloparatide, which is&#x000a0;vital to ensure optimal patient care and prevent disease progression.&#x000a0;This activity reviews the indications, mechanism of action, administration, pharmacokinetics, and associated warnings related to abaloparatide.&#x000a0;By enhancing the expertise of healthcare professionals with evidence-based strategies, this activity seeks to empower clinicians to incorporate abaloparatide into clinical practice seamlessly. This contribution aims to improve patient outcomes in the management of osteoporosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for abaloparatide therapy, considering postmenopausal women at high risk of fractures and those intolerant or unresponsive to traditional osteoporosis treatments.</p></list-item><list-item><p>Implement proper administration techniques, emphasizing subcutaneous injection and supplementing with calcium and vitamin D if dietary intake is inadequate.</p></list-item><list-item><p>Select appropriate dosages and durations of abaloparatide based on individual patient characteristics and response to treatment.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams, fostering a holistic approach to osteoporosis management, and seek specialist input when necessary.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148092">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148092.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), is used to manage and treat&#x000a0;osteoporosis. Osteoporosis is characterized by reduced bone mineral density (BMD) due to changes in bone microstructure, resulting in an elevated risk of fractures. BMD is commonly measured utilizing a dual-energy x-ray absorptiometry (DEXA or DXA) scan to assess BMD.<xref ref-type="bibr" rid="article-148092.r1">[1]</xref></p>
        <p>A DEXA scan reports the <italic toggle="yes">t</italic>-score, measured in SDs, and reflects the difference between the patient's measured BMD and the mean value of BMD. The risk of fracture increases as bone density decreases.</p>
        <list list-type="bullet">
          <list-item>
            <p>A <italic toggle="yes">t</italic>-score between &#x02212;1 and +1 reflects healthy bone.</p>
          </list-item>
          <list-item>
            <p>A <italic toggle="yes">t</italic>-score between &#x02212;1.0 and &#x02212;2.5 reflects the diagnosis of osteopenia.</p>
          </list-item>
          <list-item>
            <p>A <italic toggle="yes">t</italic>-score below &#x02212;2.5 reflects a diagnosis of osteoporosis.</p>
          </list-item>
        </list>
        <p>The US Food and Drug Administration (FDA) has approved abaloparatide use&#x000a0;in postmenopausal women at high risk of fracture due to osteoporosis.<xref ref-type="bibr" rid="article-148092.r2">[2]</xref> In addition, abaloparatide is frequently prescribed for individuals who exhibit intolerance to or have not responded to conventional osteoporosis treatments.<xref ref-type="bibr" rid="article-148092.r3">[3]</xref><xref ref-type="bibr" rid="article-148092.r4">[4]</xref>&#x000a0;In the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), subcutaneous abaloparatide significantly reduced the risk of new vertebral and nonvertebral fractures and clinical and major osteoporotic fractures compared to placebo. In the ACTIVE trial, 86% relative risk reduction (RRR) in new vertebral fractures and 43% RRR in nonvertebral fractures were observed.<xref ref-type="bibr" rid="article-148092.r5">[5]</xref>&#x000a0;The use of abaloparatide is not recommended for more than&#x000a0;2 years during a patient's lifetime.</p>
        <p>Traditional therapy for osteoporosis includes bisphosphonates and teriparatide.&#x000a0;Studies have compared the efficacy of conventional treatment to abaloparatide. In a double-blind, controlled, randomized phase II clinical trial, the safety and efficacy of abaloparatide were assessed&#x000a0;compared to teriparatide and placebo. Among these treatment groups, abaloparatide demonstrated superiority in enhancing overall BMD.&#x000a0;A comparative study comparing&#x000a0;2 sequential therapies (2 years of initial teriparatide followed by alendronate therapy and&#x000a0;2 years of abaloparatide followed by alendronate therapy) demonstrated that abaloparatide followed by alendronate has a greater treatment efficacy.&#x000a0;</p>
        <p>Abaloparatide can be combined or administered before antiresorptive therapies such as bisphosphonates to maximize effects.<xref ref-type="bibr" rid="article-148092.r6">[6]</xref><xref ref-type="bibr" rid="article-148092.r7">[7]</xref>&#x000a0;Abaloparatide is not recommended in pediatric patients with open epiphyses or genetic predispositions to bone malignancies. The effects of abaloparatide on pregnancy, breastfeeding mothers, breastfed infants, milk production, and the pediatric population are unknown.&#x000a0;The clinical practice guidelines from the American College of Endocrinology support the use of abaloparatide for postmenopausal osteoporosis, endorsing&#x000a0;the capacity to enhance BMD and decrease the likelihood of both vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.<xref ref-type="bibr" rid="article-148092.r8">[8]</xref>&#x000a0;As osteoporosis primarily affects postmenopausal women, it is&#x000a0;crucial to provide clinicians with essential knowledge about abaloparatide, which is&#x000a0;vital to ensure optimal patient care and prevent disease progression.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteoporosis in postmenopausal women at high risk for fracture.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increasing bone density in males with osteoporosis and an elevated risk of fractures or in patients who have demonstrated ineffectiveness or intolerance to other osteoporosis treatments.<xref ref-type="bibr" rid="article-148092.r9">[9]</xref><xref ref-type="bibr" rid="article-148092.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abaloparatide is utilized off-label for symptomatic pseudarthrosis in patients with metabolic syndromes.<xref ref-type="bibr" rid="article-148092.r6">[6]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abaloparatide can also be used to treat epididymitis and orchitis.<xref ref-type="bibr" rid="article-148092.r11">[11]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abaloparatide prevents bone loss resulting from ovariectomy, orchiectomy, and prolonged use of glucocorticoids while also aiding in fracture healing.<xref ref-type="bibr" rid="article-148092.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In cases of glucocorticoid-induced osteoporosis, the American College of Rheumatology conditionally suggests prioritizing the use of parathyroid hormone/PTHrP analogs such as abaloparatide over anti-resorptive medications for patients at an extremely high risk of fractures.<xref ref-type="bibr" rid="article-148092.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-148092.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Abaloparatide, a PTHrP, is a selective parathyroid hormone receptor type 1 (PTH1R) agonist.<xref ref-type="bibr" rid="article-148092.r14">[14]</xref>&#x000a0;As an agonist, anabolic activity on PTH1R on osteoblasts stimulates&#x000a0;the Gs-protein&#x02013;mediated cyclic adenosine monophosphate (cAMP) pathway, which activates phospholipase C (PLC) and phosphokinase A (PKA) to increase osteoblast activity.&#x000a0;Abaloparatide shifts the balance of bone remodeling to favor bone formation by osteoblasts with a minimal increase in osteoclast bone resorption.&#x000a0;This leads to increases in the formation of bone at periosteal, trabecular, and endocortical surfaces.<xref ref-type="bibr" rid="article-148092.r15">[15]</xref>&#x000a0;</p>
        <p>Recent studies suggest that parathyroid hormone or PTHrP analogs can differentiate between R0 and RG conformations of PTH1R. Binding to the R0 conformation of PTH1R induces a longer-lasting signaling response that gradually increases cAMP.<xref ref-type="bibr" rid="article-148092.r16">[16]</xref><xref ref-type="bibr" rid="article-148092.r17">[17]</xref>&#x000a0;This leads to an increased risk of hypercalcemia due to increased osteoclast activity, as seen with teriparatide.</p>
        <p>The binding capacity of abaloparatide to the 2 high-affinity PTH1R conformations was evaluated using radioligand competition methods. Abaloparatide exhibited greater selectivity for the RG conformation, with weak binding to R0. The anabolic effects of abaloparatide can be explained by&#x000a0;the greater affinity for RG, which leads to a rapid and swift increase in cAMP signaling while maintaining low osteoclast resorption.<xref ref-type="bibr" rid="article-148092.r18">[18]</xref>&#x000a0;</p>
        <p>This explains why patients&#x000a0;prescribed abaloparatide are less likely to develop hypercalcemia than those&#x000a0;prescribed teriparatide. A study was conducted to determine the efficacy and safety of abaloparatide in increasing BMD in Japanese patients with osteoporosis at high-risk fractures.&#x000a0;The results showed that treatment with subcutaneous abaloparatide (80 &#x000b5;g once daily) led to significant increases in serum markers of bone formation (procollagen type 1 N-terminal propeptide or P1NP) and bone resorption (cross-linked C-terminal telopeptide of type 1 collagen or CTX) compared to placebo.<xref ref-type="bibr" rid="article-148092.r19">[19]</xref></p>
        <p>Abaloparatide has off-label effects by activating Gq and &#x003b2;-arrestin-1 mechanisms in target cells such as the testis and epididymis to alleviate symptoms of epididymitis and orchitis.<xref ref-type="bibr" rid="article-148092.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The absolute bioavailability following the administration of 80 mcg of abaloparatide in healthy women is 36%.</p>
        <p><bold>Distribution:</bold>&#x000a0;Abaloparatide exhibits an approximate volume of distribution of 50 L, with plasma protein binding estimated at around 70%.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Abaloparatide peptide fragments are primarily eliminated through renal excretion after nonspecific proteolytic degradation.</p>
        <p><bold>Elimination:</bold> The mean half-life of abaloparatide is approximately 1 hour.<xref ref-type="bibr" rid="article-148092.r16">[16]</xref><xref ref-type="bibr" rid="article-148092.r20">[20]</xref>&#x000a0;Abaloparatide is predominantly eliminated from the body through the kidneys. Dosage adjustments are not necessary for women with mild, moderate, or severe renal impairment. However, close monitoring for adverse reactions is required for women with severe impairment.<xref ref-type="bibr" rid="article-148092.r21">[21]</xref></p>
      </sec>
      <sec id="article-148092.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Abaloparatide can be administered to patients through subcutaneous injection at a recommended dosage&#x000a0;of 80 mcg/day into the periumbilical region of the abdomen. Transdermal patches can serve as a suitable alternative for patients who prefer to avoid injectables, potentially enhancing medication adherence. The patch utilizes a microneedle system to deliver variable doses of abaloparatide at 50 mcg, 100 mcg, and 150 mcg daily for up to 6 months.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Abaloparatide is delivered through subcutaneous injection using a single-patient-use prefilled pen designed for 30 doses. If the patient's dietary intake of calcium and vitamin D is insufficient, supplementation should accompany subcutaneous administration of abaloparatide. For the initial few doses, the patient should be in an environment where they can sit or lie down, as orthostatic hypotension may occur within 4 hours of the injection.<xref ref-type="bibr" rid="article-148092.r22">[22]</xref></p>
        <p>Transdermal patches&#x000a0;are preferred by individuals who prefer to avoid injectables, potentially enhancing medication adherence. The transdermal patch is a novel mode of administration and is currently&#x000a0;under evaluation in clinical trials. To administer abaloparatide intradermally, the medication is applied to the thigh for a duration of 5 minutes.<xref ref-type="bibr" rid="article-148092.r20">[20]</xref>&#x000a0;</p>
        <p>In a randomized, open-label, active-controlled study comprising 500 patients&#x000a0;with postmenopausal osteoporosis with a high risk for fractures, the efficacy and safety of the transdermal patch were compared to the subcutaneous injection of abaloparatide. The subcutaneous abaloparatide injection resulted in 3.7% and 3.4% increases in total bone density in the hip and femoral neck, respectively.</p>
        <p>The transdermal patch showed 2.0% and 1.9% increases in total hip and femoral neck bone density, respectively. Although transdermal patches prove to be safer and more tolerable, with fewer subjects withdrawing, interrupting, or discontinuing the patch compared to subcutaneous injection, it is unknown whether transdermal administration reduces vertebral fractures.<xref ref-type="bibr" rid="article-148092.r23">[23]</xref></p>
        <p>The efficacy of the transdermal patch was compared to a placebo control group, with results indicating a reduction in nonvertebral fractures, increased BMD of the hip, spine, and femoral neck, and reduced incidence of hypercalcemia. Based on clinical studies, 80 mcg of abaloparatide is recommended for administration once daily via injection into the periumbilical region. Abaloparatide should not be used for more than&#x000a0;2 years in a patient's lifetime because of the unknown relevance of rodent osteosarcoma findings to humans.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No dosage adjustment for abaloparatide is specified in the manufacturer's labeling.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Patients with severe renal impairment should use abaloparatide cautiously, as the drug is eliminated through the kidneys. Dosage adjustments are unnecessary for patients with mild-to-moderate renal impairment.<xref ref-type="bibr" rid="article-148092.r15">[15]</xref><xref ref-type="bibr" rid="article-148092.r24">[24]</xref>&#x000a0;</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Abaloparatide is not recommended for females of reproductive age due to a lack of data obtained from clinical studies regarding its use during pregnancy in healthy women.</p>
        <p><bold>Breastfeeding considerations:</bold> Information regarding the presence of abaloparatide in human milk, its impact on breastfed infants, or its effect on milk production is currently unavailable.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and effectiveness of abaloparatide have not been demonstrated in pediatric patients.</p>
        <p><bold>Older patients:</bold>&#x000a0;No discernible differences in the overall safety or effectiveness of abaloparatide have been observed between older and younger patient populations.</p>
      </sec>
      <sec id="article-148092.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Effects</bold>
</p>
        <p>Abaloparatide is well tolerated and has mild adverse effects.&#x000a0;Patients may experience nausea, dizziness, headache, palpitations, and hypercalciuria.<xref ref-type="bibr" rid="article-148092.r25">[25]</xref>&#x000a0;Abaloparatide has been associated with supraventricular extrasystoles and orthostatic hypotension.<xref ref-type="bibr" rid="article-148092.r19">[19]</xref>&#x000a0;The common (&#x02265;5%) treatment-emergent adverse drug reactions in men with osteoporosis are&#x000a0;injection site reactions, nasopharyngitis, arthralgia, bronchitis, and hypertension.<xref ref-type="bibr" rid="article-148092.r10">[10]</xref>&#x000a0;</p>
        <p>The adverse effects reported from a randomized, double-blind, placebo-controlled trial among postmenopausal women with osteoporosis receiving 80 mcg of abaloparatide daily for 18 months&#x000a0;<xref ref-type="bibr" rid="article-148092.r2">[2]</xref>&#x000a0;include hypercalcemia (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Abaloparatide, at therapeutic concentrations, does not induce or inhibit cytochrome P450 enzymes. Currently, evidence does not exist to suggest any significant drug interactions.</p>
      </sec>
      <sec id="article-148092.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Abaloparatide is contraindicated in individuals with a history of systemic hypersensitivity to either abaloparatide or its excipients. Cases of eczema and urticaria have been reported.<xref ref-type="bibr" rid="article-148092.r19">[19]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Abaloparatide previously carried a boxed warning for an increased risk of osteosarcoma, but the FDA has removed this warning&#x000a0;when retaining information about osteosarcoma as a caution. In a 2-year animal study, abaloparatide administration showed increased events of osteosarcoma and osteoblastoma. A comprehensive pathology study of rats undergoing prolonged parathyroid hormone analog treatment exhibited increased rates of osteosarcoma, osteosarcoma-related mortality, and metastatic potential.<xref ref-type="bibr" rid="article-148092.r26">[26]</xref>&#x000a0;This is not advisable in patients who have open epiphyses or those who have a genetic predisposition to osteosarcoma.</p>
        <p>Abaloparatide use is also not recommended in patients with Paget disease, idiopathic increased alkaline phosphatase levels, open epiphyseal plates, or bone malignancies. Abaloparatide should not be given to patients who have previously undergone implant radiation therapy or external beam radiotherapy that involved their skeleton.<xref ref-type="bibr" rid="article-148092.r27">[27]</xref>&#x000a0;There is an increased risk of hypercalciuria, urolithiasis, and postural hypotension.<xref ref-type="bibr" rid="article-148092.r28">[28]</xref><xref ref-type="bibr" rid="article-148092.r29">[29]</xref></p>
      </sec>
      <sec id="article-148092.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Abaloparatide use increases the risk of osteosarcoma and osteosarcoma-related mortality.<xref ref-type="bibr" rid="article-148092.r26">[26]</xref> Compared to teriparatide, another parathyroid hormone analog, abaloparatide, has a reduced incidence of hypercalcemia. Patients with preexisting conditions of severe renal impairment, hypercalcemia, or primary hyperparathyroidism should be closely monitored for hypercalciuria or active urolithiasis while taking abaloparatide.&#x000a0;</p>
        <p>The injection site should be monitored for reactions, and administration should be stopped if a reaction does occur. Blood pressure should be monitored after injection to evaluate the patient for orthostatic hypotension.<xref ref-type="bibr" rid="article-148092.r30">[30]</xref><xref ref-type="bibr" rid="article-148092.r19">[19]</xref>&#x000a0;The Endocrine Society guideline&#x000a0;recommends monitoring bone turnover markers, such as serum C-terminal cross-linking telopeptide for antiresorptive treatment or procollagen type 1 N-terminal propeptide for bone anabolic therapy, as an approach to identify insufficient response or non-adherence to therapy.<xref ref-type="bibr" rid="article-148092.r3">[3]</xref>&#x000a0;For&#x000a0;abaloparatide,&#x000a0;procollagen type 1 N-terminal propeptide&#x000a0;can be obtained to monitor response to therapy.<xref ref-type="bibr" rid="article-148092.r10">[10]</xref></p>
      </sec>
      <sec id="article-148092.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Symptoms of abaloparatide toxicity include headache, nausea, asthenia, and vertigo.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No specific antidote for abaloparatide toxicity currently exists. If an overdose is suspected, abaloparatide should be discontinued by closely monitoring calcium and phosphorus levels. Supportive measures should be implemented.</p>
      </sec>
      <sec id="article-148092.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Osteoporosis is a chronic disease that decreases BMD and increases the risk of fractures. Managing osteoporosis requires an empathetic interdisciplinary team of rheumatologists, endocrinologists, orthopedic surgeons, nutritionists, nurses, nuclear medicine technicians, and physical therapists to diagnose, treat, and rehabilitate patients.</p>
        <p>Abaloparatide is a human&#x000a0;PTHrP analog that is FDA-approved in postmenopausal women with osteoporosis at a high fracture risk to reduce vertebral and nonvertebral fractures. Patients should be educated on postmenopausal osteoporosis, self-treatment with abaloparatide, and possible adverse effects. In addition,&#x000a0;dietician intervention&#x000a0;is beneficial in ensuring the patient's adequate calcium and vitamin D intake.</p>
        <p>Individuals who experience fractures or bone breakage should be treated by orthopedic surgeons and physical therapists for rehabilitation, leading to improved quality of life. Rheumatologists and endocrinologists should maintain follow-ups to monitor calcium and phosphorus levels and assess for hypercalcemia or other adverse effects. Abaloparatide is associated with an increased risk of osteosarcoma. Thus, individuals taking abaloparatide may require a nuclear medicine technician to monitor them for the development of malignancies or possible metastasis. The interprofessional team should be continuously updated on the patient's status and osteoporosis management guidelines.</p>
        <p>Abaloparatide treatment is self-administered in an environment where the patient can sit or stand if orthostatic hypotension occurs. Patients&#x000a0;without adequate calcium or vitamin D should be advised to take supplements.</p>
        <p>Abaloparatide use is indicated in postmenopausal women and not in females of reproductive potential. The effects of abaloparatide on pregnancy, breastfeeding mothers, breastfed infants, milk production, and the pediatric population are unknown. Abaloparatide is not recommended in pediatric patients with open epiphyses or genetic predispositions to bone malignancies.<xref ref-type="bibr" rid="article-148092.r31">[31]</xref></p>
        <p>Patient education, improved clinician-patient communication, and ease of medication administration all play a significant role in successful treatment initiation, management, and improvement of patient outcomes. An interprofessional team approach and open communication between clinicians optimize the treatment response to abaloparatide.</p>
      </sec>
      <sec id="article-148092.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148092">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148092/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148092">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148092.s11">
        <title>References</title>
        <ref id="article-148092.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Porter</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Osteoporosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">28722930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sleeman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide: A new pharmacological option for osteoporosis.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2019</year>
            <month>Jan</month>
            <day>25</day>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>130</fpage>
            <page-range>130-135</page-range>
            <pub-id pub-id-type="pmid">30689744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>1595</fpage>
            <page-range>1595-1622</page-range>
            <pub-id pub-id-type="pmid">30907953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wentworth</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>New Frontiers in Osteoporosis Therapy.</article-title>
            <source>Annu Rev Med</source>
            <year>2020</year>
            <month>Jan</month>
            <day>27</day>
            <volume>71</volume>
            <fpage>277</fpage>
            <page-range>277-288</page-range>
            <pub-id pub-id-type="pmid">31509477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reginster</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lewiecki</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>540</fpage>
            <page-range>540-545</page-range>
            <pub-id pub-id-type="pmid">29951742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shoback</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>105</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32068863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cornelissen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Si</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bours</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Bot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van den Bergh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reginster</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hiligsmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.</article-title>
            <source>Pharmacoeconomics</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-209</page-range>
            <pub-id pub-id-type="pmid">33026634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camacho</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Petak</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diab</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Eldeiry</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Farooki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewiecki</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McClung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wimalawansa</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE <italic>EXECUTIVE SUMMARY</italic>.</article-title>
            <source>Endocr Pract</source>
            <year>2020</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>564</fpage>
            <page-range>564-570</page-range>
            <pub-id pub-id-type="pmid">32427525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostenuik</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health.</article-title>
            <source>Curr Osteoporos Rep</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>386</fpage>
            <page-range>386-400</page-range>
            <pub-id pub-id-type="pmid">37289382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czerwinski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Plebanski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Recknor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vokes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lewiecki</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knychas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kendler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orwoll</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pearman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Mitlak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.</article-title>
            <source>J Bone Miner Res</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>2435</fpage>
            <page-range>2435-2442</page-range>
            <pub-id pub-id-type="pmid">36190391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Activation of PTH1R alleviates epididymitis and orchitis through Gq and &#x003b2;-arrestin-1 pathways.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2021</year>
            <month>Nov</month>
            <day>09</day>
            <volume>118</volume>
            <issue>45</issue>
            <pub-id pub-id-type="pmid">34740971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brent</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide: A review of preclinical and clinical studies.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>15</day>
            <volume>909</volume>
            <fpage>174409</fpage>
            <pub-id pub-id-type="pmid">34364879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humphrey</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Danila</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Magrey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Womack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abdulhadi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cheah</surname>
                <given-names>JTL</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haseltine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moledina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Punni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rinden</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wysham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Uhl</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>2405</fpage>
            <page-range>2405-2419</page-range>
            <pub-id pub-id-type="pmid">37884467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riis</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Alexandersen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zerbini</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cosman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>C</given-names>
              </name>
              <collab>ACTIVE Study Investigators</collab>
            </person-group>
            <article-title>Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Aug</month>
            <day>16</day>
            <volume>316</volume>
            <issue>7</issue>
            <fpage>722</fpage>
            <page-range>722-33</page-range>
            <pub-id pub-id-type="pmid">27533157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merlotti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Falchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiodini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gennari</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>805</fpage>
            <page-range>805-811</page-range>
            <pub-id pub-id-type="pmid">30856013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dempster</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Recknor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Leder</surname>
                <given-names>BZ</given-names>
              </name>
              <name>
                <surname>Annett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ominsky</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mitlak</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.</article-title>
            <source>J Bone Miner Res</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>644</fpage>
            <page-range>644-653</page-range>
            <pub-id pub-id-type="pmid">33434314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brent</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;el</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>588773</fpage>
            <pub-id pub-id-type="pmid">33162940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hattersley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Corbin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bahar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gardella</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.</article-title>
            <source>Endocrinology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-9</page-range>
            <pub-id pub-id-type="pmid">26562265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sone</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Sep</month>
            <day>28</day>
            <volume>107</volume>
            <issue>10</issue>
            <fpage>e4222</fpage>
            <page-range>e4222-e4231</page-range>
            <pub-id pub-id-type="pmid">35977548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Troy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Annett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schense</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mitlak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.</article-title>
            <source>Clin Drug Investig</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-285</page-range>
            <pub-id pub-id-type="pmid">33638863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1363</fpage>
            <page-range>1363-1368</page-range>
            <pub-id pub-id-type="pmid">28624872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussar</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>New Drugs 2018, part 3.</article-title>
            <source>Nursing</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>32</fpage>
            <page-range>32-43</page-range>
            <pub-id pub-id-type="pmid">30192268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tella</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kommalapati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>May</month>
            <day>31</day>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e1300</fpage>
            <pub-id pub-id-type="pmid">28680788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mitlak</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dabrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Papapoulos</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>2097</fpage>
            <page-range>2097-2102</page-range>
            <pub-id pub-id-type="pmid">31418585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontalis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kenanidis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kotronias</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Papachristou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anagnostis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Potoupnis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsiridis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>1123</fpage>
            <page-range>1123-1134</page-range>
            <pub-id pub-id-type="pmid">30958709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jolette</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Attalla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Mellal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Trimm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ominsky</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparing the incidence of bone tumors in rats chronically exposed&#x000a0;to the selective PTH type 1 receptor agonist abaloparatide&#x000a0;or&#x000a0;PTH(1-34).</article-title>
            <source>Regul Toxicol Pharmacol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>86</volume>
            <fpage>356</fpage>
            <page-range>356-365</page-range>
            <pub-id pub-id-type="pmid">28389324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Ing</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of CT Attenuations at L1 and L5.</article-title>
            <source>J Endocr Soc</source>
            <year>2022</year>
            <month>Oct</month>
            <day>26</day>
            <volume>6</volume>
            <issue>12</issue>
            <fpage>bvac152</fpage>
            <pub-id pub-id-type="pmid">36330291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewiecki</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Czerwinski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Recknor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Strzelecka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nattrass</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Annett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pearman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mitlak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.</article-title>
            <source>J Bone Miner Res</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1404</fpage>
            <page-range>1404-1414</page-range>
            <pub-id pub-id-type="pmid">37417725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>LeBoff</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Osteoanabolic Agents for Osteoporosis.</article-title>
            <source>J Endocr Soc</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>2</volume>
            <issue>8</issue>
            <fpage>922</fpage>
            <page-range>922-932</page-range>
            <pub-id pub-id-type="pmid">30087947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imel</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Starzyk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gliklich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.</article-title>
            <source>Osteoporos Int</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>2413</fpage>
            <page-range>2413-2424</page-range>
            <pub-id pub-id-type="pmid">32696118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148092.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brent</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies.</article-title>
            <source>Pharmacol Ther</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>244</volume>
            <fpage>108383</fpage>
            <pub-id pub-id-type="pmid">36933702</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
